Alessandra Bertola
Overview
Explore the profile of Alessandra Bertola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palumbo A, Falco P, Ambrosini M, Petrucci M, Musto P, Caravita T, et al.
Eur J Haematol
. 2005 Sep;
75(5):391-5.
PMID: 16191088
Objectives: High-dose therapy followed by autologous transplant (AT) is the effective induction treatment for newly diagnosed multiple myeloma (MM) patients. The best salvage therapy has not been defined; treatment options...
2.
Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, et al.
Cancer
. 2005 Aug;
104(7):1428-33.
PMID: 16116606
Background: Thalidomide is an immunomodulatory drug with strong antimyeloma activity. It is an effective treatment for multiple myeloma at disease recurrence and at diagnosis, both as a single agent and...
3.
Ladetto M, Vallet S, Trojan A, DellAquila M, Monitillo L, Rosato R, et al.
Blood
. 2005 Feb;
105(12):4784-91.
PMID: 15731178
Cyclooxygenase 2 (COX-2) is an inflammation-associated enzyme involved in the pathogenesis of many solid tumors, but little is known about its presence and role in hematologic neoplasms. Multiple myeloma (MM)...
4.
Falco P, Bertola A, Bringhen S, Cavallo F, Boccadoro M, Palumbo A
Hematol J
. 2004 Sep;
5(5):456-7.
PMID: 15448677
No abstract available.
5.
Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, et al.
Hematol J
. 2004 Aug;
5(4):318-24.
PMID: 15297848
Purpose: The efficacy of low-dose thalidomide (THAL) plus dexamethasone (DEX) has been evaluated in myeloma. The clinical outcome of patients treated with THAL-DEX was compared with that of a control...
6.
Palumbo A, Bringhen S, Petrucci M, Musto P, Rossini F, Nunzi M, et al.
Blood
. 2004 Jul;
104(10):3052-7.
PMID: 15265788
High-dose therapy is an effective standard treatment for multiple myeloma patients. Evidence that intermediate-dose therapy improves survival is limited. At diagnosis, about 70% of patients are older than 65. Intermediate-dose...
7.
Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, et al.
Lancet Oncol
. 2004 Jul;
5(7):430-42.
PMID: 15231250
Multiple myeloma (MM) is a disease of plasma cells that has fatal consequences. New insights into the biology of MM have identified molecular mechanisms that hold promise as therapeutic targets....
8.
Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L, et al.
Haematologica
. 2002 Aug;
87(8):846-50.
PMID: 12161361
Background And Objectives: Since optimal collection of peripheral blood progenitor cells (PBPC) remains crucial for high-dose therapy in patients with multiple myeloma (MM) in relapse phase or refractory to chemotherapy,...